Janssen - Legend Biotech CAR-T Collaboration

Sexton Riley LLP Represents Janssen in Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy

December 2017

​Sexton Riley LLP represented Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, in a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Ireland Limited (“Legend”), subsidiaries of Genscript Biotech Corporation, to develop, manufacture and commercialize a chimeric antigen receptor (CAR) T-cell drug candidate, LCAR-B38M, which specifically targets the B-cell maturation antigen (BCMA).

Under terms of the agreement, Legend will grant Janssen a worldwide license to jointly develop and commercialize LCAR-B38M in multiple myeloma with the Legend team of experts.

The companies have entered into a 50/50 percent cost-sharing/profit-split arrangement, except in Greater China, where Janssen and Legend have a 30/70 percent cost-sharing/profit-split arrangement. Janssen made an upfront payment of $350 million.

The Janssen press release is here.

Recent Posts

See All

Sexton Riley LLP is proud to announce that Julienne Hearn has joined the firm as a partner, as of October 1, 2021. Julienne is a corporate and intellectual property lawyer with extensive experience ad

Sexton Riley LLP Represents Janssen Affiliate Cilag GmbH International in Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab December 2018 ​Sexton Riley LLP